PhRMA white paper on ADME pharmacogenomics

作者：Williams J Andrew^*; Andersson Tommy; Andersson Tommy B; Blanchard Rebecca; Behm Martin Otto; Cohen Nadine; Edeki Timi; Franc Monique; Hillgren Kathleen M; Johnson Keith J; Katz David A; Milton Mark N; Murray Bernard P; Polli Joseph W; Ricci Deb; Shipley Lisa A; Vangala Subrahmanyam; Wrighton Steven A

来源：JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48(7): 849-889.

DOI：10.1177/0091270008319329

• pharmacogenomics
• ADME
• PhRMA
• drug-metabolizing enzymes
• genotyping

Pharmacogenomic (PGx) research on the absorption, distribution, metabolism, and excretion (ADME) properties of drugs has begun to have impact for both drug development and utilization. To provide a cross-industry perspective on the utility of ADME PGx, the Pharmaceutical Research and Manufacturers of America (PhRMA) conducted a survey of major pharmaceutical companies on their PGx practices and applications during 2003-2005. This white paper summarizes and interprets the results of the survey, highlights the contributions and applications of PGx by industrial scientists as reflected by original research publications, and discusses changes in drug labels that improve drug utilization by inclusion of PGx information. In addition, the paper includes a brief review on the clinically relevant genetic variants of drug-metabolizing enzymes and transporters most relevant to the pharmaceutical industry.

• 出版日期2008-7